Clinical research for rare disease: opportunities, challenges, and solutions. (25/70)

Incentives for orphan drug research and development in the United States. (26/70)

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? (27/70)

Pivotal studies of orphan drugs approved for neurological diseases. (28/70)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study. (29/70)

Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. (30/70)

The loneliness of fighting a rare cancer. (31/70)

Therapies for inborn errors of metabolism: what has the orphan drug act delivered? (32/70)

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9